Paysign, Inc. (NASDAQ: PAYS) reported Q2 EPS of ($0.02), $0.01 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $6.65 million versus the consensus estimate of $6.82 million.

GUIDANCE:

Paysign, Inc. sees FY2021 revenue of $29-32 million, versus the consensus of $30.57 million.

• “For the full year 2021, we continue to forecast total revenue to be in the range of $29.0 million to $32.0 million, reflecting growth of 20% to 32%. We are raising our adjusted EBITDA forecast to be in the range of $0.75 million to $1.90 million due to the better-than-expected results this quarter and higher gross profit margin expectations given operating leverage in our model as plasma volumes recover and we add more pharma programs. We are raising our gross profit margin forecast by 150 basis points to 46.5%, which is an increase of 790 basis points over 2020. Operating expenses are expected to increase modestly between $18.0 million to $18.5 million, or 2.0% to 4.9%,” Baker concluded.

For earnings history and earnings-related data on Paysign, Inc. (PAYS) click here.